Immuno-oncology
Conference Coverage
Checkpoint inhibitor seems safe and effective for patients with HIV
MUNICH – No immune-related adverse events or deaths due to drug toxicity occurred in cancer patients with HIV treated with nivolumab.
Conference Coverage
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinib
MUNICH – Avelumab and axitinib offered better progression-free survival than did sunitinib as first-line therapy for advanced renal cell carcinoma...
Conference Coverage
Finally, immunotherapy shows benefit in TNBC
MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...
From the Journals
Kymriah appears cost effective in analysis
The latest study on the CAR T therapy tisagenlecleucel for pediatric leukemia says it may be cost effective, provided that the long-term benefits...
Conference Coverage
Researchers consider R/R ALL drugs in the first-line setting
CHICAGO –
News
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
This sets the stage for
Conference Coverage
DETERRED trial: Concurrent atezolizumab, CRT shows promise in LA-NSCLC
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...
From the Journals
Epacadostat plus pembrolizumab shows promise in advanced solid tumors
Investigational drug epacadostat plus pembrolizumab demonstrated promising antitumor activity and safety in patients with advanced solid tumors....
Conference Coverage
B-cell maturation antigen targeted in myeloma trials
NEW YORK – So far,
Conference Coverage
IMpower133: Atezolizumab plus standard chemotherapy boosted survival in ES-SCLC
Adding atezolizumab to standard first-line ES-SCLC treatment significantly improved overall survival and progression-free survival in the...
From the Journals
Checkpoint inhibitor linked to antiphospholipid syndrome in melanoma patient
A melanoma patient receiving pembrolizumab was diagnosed with antiphospholipid syndrome that resolved following discontinuation of that treatment...